Federal agencies urged to require same names for biosimilars
In a letter sent Tuesday to the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA), the Biosimilars Council joined a group of health care stakeholders arguing adopting distinguishable names for biosimilars and biologics would create hurdles for patient's access to new, more affordable medicines. Read More »